Akeso To Boost Manufacturing Of Cancer Drug

Chronological Source Flow
Back

AI Fusion Summary

Akeso's CFO Bing Wang announced substantial investment to expand production of its lung‑cancer drug for China and U.S. markets, following encouraging ASCO results. Meanwhile, Folarin Oyenuga details how systematic EBS optimization achieved notable annual cost savings.
Community Comments
Loading updates...
0